THERAPY DOSSIER · th-97ca26a7865f

Hypoxic preconditioned adipose derived stem cells

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23110692 ↗2012Reported benefit

Tissue engraftment of hypoxic-preconditioned adipose-derived stem cells improves flap viability.

RatIschaemia-reperfusionOther / unspecifiedLewisn = 21 rats in three groupsLocal injection into the distal third of the flap1 x 10^6 cellsAt the time of flap elevation

Model: Ischaemic dorsal surgical skin flap

Hypoxic preconditioned cells significantly improved flap viability at day 7 with more CD31 positive cells, although the authors describe the effects as modest.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…